Explanipedia

Risk factors for surgical site infection in colorectal surgery: An observational study in a Vietnamese tertiary hospital Open

Nhat Trung Doan, Meifeng Tu, Thach Tran, Tran Cong Bao Phung, Vo Hoang Kim Tuyen Dang , et al. · 2025

Surgical site infection (SSI) represents a major challenge in colorectal surgery, with significantly higher incidence rates than those in other surgical specialties. This study aimed to identify the prevalence and risk factors of SSI follo…

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial Open

Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng , et al. · 2024

Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplat…

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma Open

Zhitao Ying, Ting He, Shanzhao Jin, Xiaopei Wang, Wen Zheng , et al. · 2022

These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T, IM19, which is promising for further development and clinical investigation.

A Durable 4-1BB-based CD19 CAR-T Cell for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Open

Zhitao Ying, Ting He, Shanzhao Jin, Xiaopei Wang, Wen Zheng , et al. · 2021

Backgroud : CD19-directed chimeric antigen receptor T (CAR-T) cell therapy has shown great promise for cure of relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Previous studies reported that 4-1BB-based CD19 CAR-T was more b…

Primary mediastinal large <span>B</span> cell lymphoma Open

Yating Yu, Xifeng Dong, Meifeng Tu, Huaquan Wang · 2021

Primary mediastinal large B cell lymphoma (PMBCL) is an aggressive large B cell lymphoma originating in the mediastinum, that mainly expresses B cell surface molecules, such as CD19, CD20, CD22, andCD79a. Clinically, they are characterized…

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies Open

Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu , et al. · 2021

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies Open

Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin , et al. · 2021

Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries Open

Zijun Y. Xu‐Monette, Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov , et al. · 2020

CD5 is a pan-T-cell surface marker and is rarely expressed in diffuse large B-cell lymphoma (DLBCL). Large-scale studies of de novo CD5+ DLBCL are lacking in Western countries. In this study by the DLBCL Rituximab-CHOP Consortium, CD5 was …

Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19 Open

Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin , et al. · 2020

Backgroud : The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of CD19 + B-cell malignancies has opened a new and useful way for the treatment of malignant tumor. Nonetheless, there are still formidable chal…

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades Open

Weiping Liu, Xinqiang Ji, Yuqin Song, Xiaopei Wang, Wen Zheng , et al. · 2020

Background The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China. Methods A total o…

Mobile-deployed care management based on standardized ePRO and computer-interpretable guideline engine for Chinese lymphoma patients. Open

Ling Yan Ping, Yuqin Song, Tingting Zhang, Zhi Tao Ying, Chen Zhang , et al. · 2019

1 Background: To effectively assist lymphoma patients and their care-givers after their hospital discharge, a standard follow-up guideline for lymphoma patients was designed and encoded through a computer-interpret-able-guideline (CiG) eng…

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma Open

Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin , et al. · 2019

CD19-targeted chimeric antigen receptor-T (CAR-T) cells with CD28 or 4-1BB (28z CAR-T and BBz CAR-T) have shown great promise to treat relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). However, comparison of their clinica…

A safe and potent anti-CD19 CAR T cell therapy Open

Zhitao Ying, Xue F. Huang, Xiaoyu Xiang, Yanling Liu, Xi Kang , et al. · 2019

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma Open

Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi , et al. · 2019

MOESM3 of ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma Open

Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi , et al. · 2019

Additional file 3: Table S2. Patientsâ characteristics and correlations with the expression of p-PLCÎł1.

MOESM1 of ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma Open

Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi , et al. · 2019

Additional file 1: Figure S1. ITK inhibitor HY-11066 inhibits the proliferation of malignant T-cell lymphoma cell lines. Jurkat, Hut-78 and H9 cells were treated with the indicated concentrations of the ITK inhibitor HY-11066. The cell via…

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation Open

Zhitao Ying, Lan Mi, Nina Zhou, Xuejuan Wang, Zhi Yang , et al. · 2019

PET results before and after HSCT are useful prognostic factors for DLBCL patients receiving HSCT. Patients who responded to chemotherapy, even those with positive pre-HSCT PET, are appropriate candidates for auto-HSCT.

MOESM2 of ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma Open

Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi , et al. · 2019

Additional file 2: Table S1. Patientsâ characteristics and correlations with the expression of p-ZAP70.

PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity Open

Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su , et al. · 2018

[Clinical characteristics and survival analysis of <i>de novo</i> grade 3 or transformed follicular lymphoma patients]. Open

Zhitao Ying, H Y Feng, Mi L, Yuqin Song, X P Wang , et al. · 2018

Objective: To evaluate the clinical characteristics and survival outcomes of patients with de novo grade 3 or transformed follicular lymphoma (FL). Methods: Fifty-two patients treated at Peking University Cancer Hospital betw…

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas Open

Meng Wu, Xiaopei Wang, Yan Xie, Weiping Liu, Chen Zhang , et al. · 2018

Background: For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy fro…

[Clinical features, diagnosis, treatment, and prognosis of 99 cases with primary intestinal lymphoma]. Open

Lingyan Ping, Yuqin Song, Wen Zheng, X P Wang, Yun Xie , et al. · 2017

Objective: To investigate the clinical features, diagnosis, treatment and prognosis of primary intestinal lymphoma (PIL) . Methods: The characteristics, diagnosis, treatment methods, and follow-up outcomes of 99 PIL patients,…

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53 Open

Qingqing Cai, Meifeng Tu, Zijun Y. Xu‐Monette, Ruifang Sun, Ganiraju C. Manyam , et al. · 2017

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease Open

Yu Li, Meifeng Tu, Jorge E. Cortés, Zijun Y. Xu‐Monette, Roberto N. Miranda , et al. · 2017

Key Points HIV-negative UCD and iMCD are heterogeneous at the clinical, immunophenotypic, and pathologic levels. Complete surgical resection is the primary option of treatment of UCD, while siltuximab is more effective for iMCD than rituxi…

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma Open

Wen Zheng, Hanyun Ren, Xiaoyan Ke, Mei Xue, Yongqing Zhang , et al. · 2017

Our clinical data and observed outcomes indicate that 1 dose of PEG-ASP can replace multiple doses of native L-ASP in BFM-90, with predominantly grade 3-4 neutropenia for adult LBL, and no therapy-related deaths. The effect is similar to p…

Cerebrospinal Fluid Proteins Identification Facilitates the Differential Diagnosis of Central Nervous System Diffuse Large B Cell Lymphoma Open

Wen Zheng, Yuqin Song, Yan Xie, Ningjing Lin, Meifeng Tu , et al. · 2017

Background: Diagnosis of central nervous system (CNS) lymphoma remains a challenge. This study aimed to identify cerebrospinal fluid (CSF) proteins that distinguish patients with and without CNS lymphoma. Methods: We used one…

[Clinical analysis of thalidomide in 36 untreated patients with T-cell lymphoma]. Open

Han Yao Huang, Y. Song, W. Zheng, X P Wang, Yun Xie , et al. · 2016

[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]. Open

Weiping Liu, Xiaopei Wang, Chen Zhang, Yan Xie, Ningjing Lin , et al. · 2016

NCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP Open

Zijun Y. Xu‐Monette, Bouthaina S. Dabaja, Xiaoxiao Wang, Meifeng Tu, Ganiraju C. Manyam , et al. · 2015

Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin Open

Lijuan Deng, Yuqin Song, Ken H. Young, Shimin Hu, Ning Ding , et al. · 2015

While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little is known more than this epidemiologic evidence. We studied a cohort of 587 patients with DLBCL f…

Meifeng Tu YOU? Author Swipe